The Policlinico of Milan (Italian: Policlinico di Milano) also known as Ospedale Maggiore di Milano or Ca' Granda Ospedale Maggiore Policlinico, is one of the oldest hospitals in Italy, founded by Duke Francesco Sforza in 1456. Today it is a modern hospital with 900 beds, with wards for adults, pregnant women and children. During the first COVID-19 breakout in March 2020, 300 of those beds were readapted for COVID-19 patients.There are three emergency rooms for different categories of patients. The maternity ward (Mangiagalli Clinic) has the highest number of births in Lombardy.The Foundation is a scientific Institute for Research, Hospitalization and Health Care (IRCCS), which means that, alongside clinical activity, it promotes research programs with predominantly translational purposes. The programs are concerned with the rapid transfer of therapies from the laboratory to patients..
Objective Cenobamate is approved for treatment of focal seizures in adults, but evidence on non-seizure outcomes remains limited. This interim statistical analysis of the cenoBamate in aduLts with focal-onsEt SeizureS (BLESS) study evaluated patient- and clinician-reported outcomes for up to 52 weeks of cenobamate treatment. Methods BLESS is an observational, retrospective and prospective cohort study designed to assess the real-world effectiveness and safety of adjunctive cenobamate in adults with uncontrolled focal epilepsy. Outcomes included patient-reported health-related quality of life, sleepiness, anxiety, mood, and global functioning assessed by the 31-item Quality of Life in Epilepsy Inventory (QOLIE-31), the Epworth Sleepiness Scale (ESS), the Hospital Anxiety and Depression Scale (HADS), and the Clinical Global Impression (CGI) scales. Results A total of 377 participants were included. Among subjects with an available score at 12 (n = 197), 24 (n = 363), and 52 (n = 197) weeks, the QOLIE-31 overall score remained stable. Subjects with sustained seizure freedom at 24 weeks showed a significantly higher QOLIE-31 overall score (p = 0.041) and cognitive functioning scores (p = 0.019) compared with those who did not reach sustained seizure freedom. More than 68% of participants had normal daytime sleepiness (total ESS score 0-10) and did not report anxiety or depression according to the HADS-A and HADS-D subscales at each assessment up to 52 weeks. Clinicians rated 91.3% (n/N = 179/196), 85.7% (n/N = 300/350), and 87.4% (n/N = 167/191) of subjects as improved for their overall condition from the initiation of treatment according to the CGI-Improvement or change (CGI-I) scale, at 12, 24, and 52 weeks. Significance This interim analysis provides preliminary descriptive evidence on non-seizure outcomes in subjects treated with adjunctive cenobamate. Patient-reported outcome scores remained stable from 12 weeks and up to 52 weeks, consistent with preserved overall well-being. Better quality of life and cognitive functioning emerged in sustained vs non-sustained seizure-free participants. Based on clinicians' judgment, there was signal of improvement in overall condition compared to baseline in most treated subjects throughout the observation period.Study Registration NCT05859854.
Pulmonary vein isolation (PVI) is an established treatment for symptomatic atrial fibrillation (AF). To date, cryoballoon (CB) ablation has been the most widely adopted single-shot approach, while pulsed field ablation (PFA) has emerged as a non-thermal alternative designed to preferentially ablate myocardial tissue and reduce collateral injury. PulseSelect™ is a CE-marked and FDA approved PFA system specifically developed for PVI. We compared acute and one-year outcomes of PulseSelect PFA versus fourth-generation cryoballoon (CB4) ablation in routine clinical practice. This multicenter analysis included 254 consecutive patients undergoing first-time PVI in 10 Italian medium-volume centers between January 2024 and February 2025: 121 treated with PulseSelect and 133 with CB4. Baseline clinical and echocardiographic characteristics were prospectively collected. Procedural workflow, anesthesia strategy, procedure duration, fluoroscopy time, and periprocedural complications were assessed. Follow-up consisted of scheduled visits with rhythm monitoring, and arrhythmia recurrence was evaluated using Kaplan–Meier analysis. A total of 254 consecutive patients (mean age 62 ± 9 years, 28.3
In patients on oral anticoagulation (OAC) undergoing percutaneous coronary intervention (PCI), clopidogrel is currently the preferred antiplatelet agent to be given in double antithrombotic therapy (DAT). To explore whether aspirin could be an alternative option, a post-hoc analysis of the Italian, multi-center, prospective PERSEO (PERcutaneouS coronary intErventions in patients treated with Oral anticoagulant therapy) registry was performed. Out of the 989 patients included in the analysis, 769 (78
BACKGROUND:Antibiotics can cause adverse drug reactions (ADRs) and hypersensitivity reactions (HSRs) through a variety of mechanisms. At our hospital, patients admitted with musculoskeletal tissue infection are followed by infectious disease consultants. The pharmacist only provides the therapy after verifying the correspondence (molecule, dosage and posology) of the motivated request (RMP) with the infectious disease consultancy. The aim was to identify adverse drug reactions, report them and providing training. METHODS:Following the pharmacist's analysis of the infectious disease consultations, ADRs relating to antibiotics were identified and they were entered into the Network of Pharmacovigilance data from Italy, also managing any integrations, and subsequently collected in an Excel file. A qualitative analysis of clinical status, suspected drugs, adverse drug reactions (ADRs) description and its degree of seriousness were collected. A training course was organised "Rischio infettivo: Strumenti, best practice e approfondimenti". RESULTS:The most involved drugs were daptomycin and piperacillin tazobactam; the most observed adverse reactions were dermatological manifestations, eosinophilia, increased transaminases. Most of the reports were not serious. They organized 13 training courses and formats 400 health workers. CONCLUSIONS:Our experience confirms an under-reporting and has highlighted that the contribution to reporting by hospital doctors and nurses is closely related to the valuable work of awareness and support of hospital pharmacists. They assist clinicians in detecting phenomena that may underline the onset of adverse reactions and, consequently, carry out a reporting activity that guarantees useful information for the management of antibiotic therapy. Disseminating and discussing the results of pharmacovigilance is an aspect that motivates the healthcare professional to report. Working to increase the identification of ADRs and the consequent reporting allows us to contribute to the appropriate prescription of antibiotics, avoiding the onset of resistance and also the exposure of the individual patient to serious and disabling side effects.
